STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more
A U.S. judge rejected a bid to block Eli Lilly from running what Novo Nordisk claims is a “deceptive” advertising campaign about weight loss drugs
Novo's setback in court, House probe into PBMs, and other news dominate Pharmalot today. GSK is seeing its oncology business start to thrive, with recent approvals and a licensed medicine getting attention at an oncology conference. However, GSK still lags behind the sales of Merck's Keytruda. Meanwhile, a House lawmaker is investigating the three largest pharmacy benefit managers for allegedly targeting independent pharmacies with audits after they backed legislation that would require adjustments to payments to the retailers.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
